Study finds experimental coagulant risk for heart patients

08/30/2011 | Reuters

The addition of experimental anti-clotting drug darexaban to anti-platelet therapy resulted in a two- to fourfold increase in bleeding among patients with acute coronary syndrome, a Phase II study found. The oral factor Xa inhibitor is undergoing a test for stroke prevention in subjects with atrial fibrillation and previously showed promise in reducing blood-clot risk after orthopedic surgery.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA